The US Food and Drug Administration (FDA) has granted approval for Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic for Takeda’s Exkivity (mobocertinib).
Exkivity already secured approval from the FDA for locally advanced or metastatic non-small cell lung cancer adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
FoundationOne Liquid CDx is claimed to be the only blood-based comprehensive genomic profiling test that received the US regulator’s approval for detecting EGFR exon 20 insertion mutations to identify suitable patients to treat with Exkivity.
This qualitative next-generation sequencing-based in vitro diagnostic test has the ability to analyse over 300 cancer-related genes for genomic alteration from a simple blood sample.
It specifically analyses 324 genes by deploying circulating cell-free DNA.
The prescription use-only test received FDA approval to report short variants in 311 genes, as well as a companion diagnostic to detect patients who are expected to benefit from treatment with specific therapies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFoundation Medicine chief medical officer Mia Levy said: “Cancer is an incredibly complex disease, so it’s critical that oncologists leverage companion diagnostics, which are high-quality, well-validated genomic tests to inform treatment decisions for their patients.
“We’re proud of the work we’ve done with Takeda to develop blood and tissue-based companion diagnostics for therapies in their precision oncology pipeline, including this recent approval for Exkivity.”
